VIDEO: Efficacy win for CAR-T in update of ZUMA-7 trial at ASCO
Click Here to Manage Email Alerts
In this video, Joshua Brody, MD, discusses an update of the ZUMA-7 trial, which was presented at ASCO Annual Meeting.
He said the "critical update" of the phase 3 randomized study of axicabtagene ciloleucel (Yescarta, Kite Pharma/Gilead Sciences) vs. standardofcare therapy in relapsed/refractory large B-cell lymphoma reported overall survival benefit of second-line chimeric antigen receptor T-cell therapy.
The main result, Brody noted, is that the 42% of patients treated with CAR T cells were still progression free after 4 years, compared with only 24% of patients treated with standard of care.
"It's a gigantic efficacy benefit with CAR-T therapy, and now the new result is that we actually see significant delta in overall survival, and it's not a subtle thing; 55% of axi-cel CAR-T treated patients are still alive compared to 46% in the standard-of -care arm," Brody, director of the lymphoma immunotherapy program at The Tisch Cancer Institute at Mount Sinai, said.
"In second-line therapy, the early relapsing patients — at least up to 12 months or refractory patients — should be treated with CAR-T," he said.
Reference :
- Westin J, et al. Abstract LBA107. Presented at: ASCO Annual Meeting; June 2-6, 2023; Chicago.
Collapse
Click Here to Manage Email Alerts